Antioxidants

TILT Holdings to Report Second Quarter Results on Tuesday, August 24, 2021

Retrieved on:

Thursday, July 29, 2021

Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Entheogens, Antioxidants, Medical cannabis, Cannabis, Brand

A replay of the call will also be available for approximately 30 days.

Key Points:

A replay of the call will also be available for approximately 30 days.
Please remember to join the webcast approximately 10 minutes prior to the start time to install any necessary software that may be required to join the call.
TILT helps cannabis businesses build brands.
The CSE has neither approved nor disapproved the contents of this news release.

New Frontier Data Releases First Comparative Study on EU and US Cannabis Regulations

Retrieved on:

Wednesday, July 28, 2021

Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Antioxidants, Medical cannabis, Pharmacognosy, Cannabis

This first-of-its-kind comparative assessment concludes that the disparity in evolving regulations at the national and state levels is introducing significant uncertainty, challenges and risk for industry stakeholders globally.

Key Points:

This first-of-its-kind comparative assessment concludes that the disparity in evolving regulations at the national and state levels is introducing significant uncertainty, challenges and risk for industry stakeholders globally.
It also spotlights the importance of considering consumer sentiment and behavior in the development of regional and global regulation.
Consumer sentiment will influence regulations with 66% of cannabis consumers agreeing that legal cannabis is safer than illegal cannabis, and 77% of consumers citing potency as a very or extremely important driver in purchasing decisions.
Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with a presence in Europe, Latin America and Africa.

Fall Asleep Faster with Country Life Vitamins' Latest Launch: Melatonin 10mg, Magnesium, Zinc & Vitamin C

Retrieved on:

Thursday, July 8, 2021

Chemistry, Chemical substances, Physical sciences, Circadian rhythm, Melatonin receptor agonists, Antidepressants, Antioxidants, Melatonin, Zinc, Vitamin C

NEW YORK, July 8, 2021 /PRNewswire/ --Today, Country Life Vitamins introduces Melatonin 10mg, Magnesium, Zinc & Vitamin C to its wide range of vitamin & supplement offerings.

Key Points:

NEW YORK, July 8, 2021 /PRNewswire/ --Today, Country Life Vitamins introduces Melatonin 10mg, Magnesium, Zinc & Vitamin C to its wide range of vitamin & supplement offerings.
Taking Melatonin 10mg once daily before bed helps improve the ability to fall asleep faster.
Melatonin 10mg, Magnesium, Zinc & Vitamin C joins Country Life's robust line of sleep supplements including Stress Shield Nighttime, Gut Connection Sleep Balance, GABA Relaxer and Melatonin 1mg and 3mg.
Melatonin 10mg, Magnesium, Zinc & Vitamin C is now available on countrylifevitamins.com for $14.99/60 day supply ( Melatonin 10mg - with Magnesium, Zinc and Vitamin C (60 capsules) - Country Life Vitamins ).

P&G Launches Nervive™ Nerve Relief in the U.S.

Retrieved on:

Monday, June 28, 2021

Physical therapy, Other Consumer, Other Health, Health, General Health, Women, Seniors, Pharmaceutical, MEN, Fitness & Nutrition, Consumer, Chemical compounds, Antioxidants, Cofactors, Lipoic acid, Branches of biology, Chemical substances

View the full release here: https://www.businesswire.com/news/home/20210628005601/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20210628005601/en/
P&G Launches Nervive Nerve Relief in the U.S. (Photo: Business Wire)
Nervive launches three supplements to address different nerve care needs: Nervive Nerve Health to fortify foundational nerve health,* as well as Nerve Relief and Nerve Relief PM for occasional nerve aches, weakness, and discomfort due to aging, for relief day or night*.
Nerve Relief and Nerve Relief PM combine B-Complex Vitamins with clinically proven levels of Alpha-Lipoic Acid to relieve occasional nerve aches, weakness, and discomfort due to aging*.
Nervive, from the worlds #1-selling nerve care company, is dedicated to holistic nerve care and relief.
Developed with over 50 years of global expertise and experience in nerve care, the Nervive line-up includes:
Nervive Nerve Relief : Formulated with Alpha-Lipoic Acid, which has been shown to relieve occasional nerve aches & discomfort*, and B Complex Vitamins that nourish nerves, enhance neurotransmission, and build nerve insulation*
Nervive Nerve Relief PM : Formulated with B-Complex Vitamins and Alpha-Lipoic Acid, Nerve Relief PM relieves occasional nerve aches, weakness, & discomfort, plus helps you fall asleep naturally* with melatonin
To learn more about Nervive, visit https://www.nervivehealth.com/en-us .

Former Grassroots Cannabis Co-Founder and CEO of Big Plan Holdings rejoins cannabis industry with new operations in the Northeast

Retrieved on:

Friday, June 25, 2021

Health sciences, Herbalism, Medicinal plants, Medicine, Health care, Antiemetics, Antioxidants, Medical cannabis, Dispensary, Cannabis

They anticipate the openings of the three dispensaries in 2021 and are on the search for a state allowed fourth dispensary location.

Key Points:

They anticipate the openings of the three dispensaries in 2021 and are on the search for a state allowed fourth dispensary location.
"After taking some time to grow our family company, it is incredibly exciting to be returning to the cannabis industry.
To further capitalize on the rapidly growing cannabis industry, a wholly owned subsidiary of Big Plan Holdings acquired a single tenant property located in Macomb, Illinois that features a long-term lease with Windy City Cannabis.
Big Plan Holdings is a Nashville, Tennessee based diversified family holding company with investments in various industries across the country.

General Cannabis Submits Change of Ownership License to Colorado’s Marijuana Enforcement Division (MED) for Englewood Dispensary Location

Retrieved on:

Tuesday, June 15, 2021

Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Antioxidants, Medical cannabis, Pharmacognosy, Cannabis

DENVER, June 15, 2021 (GLOBE NEWSWIRE) -- General Cannabis Corp (OTCQB: CANN) is pleased to announce the submittal of the Change of Ownership License to the Marijuana Enforcement Division (MED) for the Englewood Dispensary location has been made.

Key Points:

DENVER, June 15, 2021 (GLOBE NEWSWIRE) -- General Cannabis Corp (OTCQB: CANN) is pleased to announce the submittal of the Change of Ownership License to the Marijuana Enforcement Division (MED) for the Englewood Dispensary location has been made.
General Cannabis Corp is a Colorado-based cannabis company with deep expertise in wholesale and retail operations as well as cultivation consulting.
General Cannabis intends to change its name to Trees after the closing of the Trees acquisition, though it will retain its trading symbol CANN.
General Cannabis Corp undertakes no duty to update any forward-looking statements made herein.

Columbia Care Signs Definitive Agreement to Acquire Medicine Man, a Rapidly Growing, Vertically Integrated Operator in the Denver Metro Area

Retrieved on:

Tuesday, June 15, 2021

We are thrilled to bring one of Colorados longest-running and most highly respected cannabis companies into the Columbia Care family.

Key Points:

We are thrilled to bring one of Colorados longest-running and most highly respected cannabis companies into the Columbia Care family.
Medicine Man brings a highly experienced and talented team of executives and employees that further bolsters Columbia Cares strong pool of talent.
Medicine Man is thrilled to announce our partnership with Columbia Care, said Sally Vander Veer, CEO of Medicine Man.
Columbia Care is known for setting the standard for compassion, professionalism, quality, care, and innovation in the rapidly expanding cannabis industry.

Resonate Blends, Inc. Seeks to Expand Its Product Development Roadmap

Retrieved on:

Thursday, June 3, 2021

Alternative medicine, Oncology, Health, Tobacco, Specialty, Fitness & Nutrition, Cosmetics, Retail, Herbalism, Medicinal plants, Cannabis smoking, Psychoactive drugs, Health sciences, Branches of biology, Antioxidants, Medical cannabis, Cannabis, Effects of cannabis, Forward-looking statement

Ms. Quinn will also serve on the Companys Advisory Board with a focus on cannabis product development and educational programs.

Key Points:

Ms. Quinn will also serve on the Companys Advisory Board with a focus on cannabis product development and educational programs.
Our first product, the Koan Cordials, currently rolling out to an enthusiastic industry response, is a perfect expression of that mission.
The company created the Resonate Systema comprehensive system of interconnected experience targets to personalize consumers relationship with Cannabis through its products.
These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements.

GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of LUMEVOQ® versus Natural History in Frontiers in Neurology

Retrieved on:

Tuesday, June 1, 2021

Treated eyes refer to all eyes (LUMEVOQ and sham) from the RESCUE, REVERSE and CLIN06 trials (N=152 eyes from 76 patients).

Key Points:

Treated eyes refer to all eyes (LUMEVOQ and sham) from the RESCUE, REVERSE and CLIN06 trials (N=152 eyes from 76 patients).
*A statistically significant difference between treated and natural history eyes is illustrated by the non-overlapping confidence intervals of the LOESS curves.
For a better characterization of LUMEVOQ efficacy, a natural history, or untreated, pool had to be assembled from patients carrying the same mutation as those in the clinical trials.
The natural history pool was formed from patients who were not treated with LUMEVOQ; they could, however, have been treated with idebenone.

Santhera Completes Capital Increase for Financing Arrangements

Retrieved on:

Thursday, May 20, 2021

Antioxidants, Idebenone, Leber's hereditary optic neuropathy, XC2, Optic neuropathy, Leber, Share, Health, Branches of biology

b"Pratteln, Switzerland, May 20, 2021 \xe2\x80\x93 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,562,375 treasury shares.\nOn May\xc2\xa019, 2021, 2,562,375 shares were issued out of the existing authorized capital as treasury shares.

Key Points:

b"Pratteln, Switzerland, May 20, 2021 \xe2\x80\x93 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,562,375 treasury shares.\nOn May\xc2\xa019, 2021, 2,562,375 shares were issued out of the existing authorized capital as treasury shares.
Santhera expects to use these shares for purposes of its financing arrangements, including the Senior Unsecured Convertible Bonds due 2024 (SAN21, CH0563348744) issued on May\xc2\xa04, 2021.
Santhera out-licensed ex-North American rights to its first approved product, Raxone\xc2\xae (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group.
For further information, please visit www.santhera.com .\nRaxone\xc2\xae is a trademark of Santhera Pharmaceuticals.\nFor further information please contact:\nThis communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG.